Predictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma
Received Date : 18 Apr 2022
Accepted Date : 10 Jun 2022
Available Online : 29 Jun 2022
Doi: 10.37047/jos.2022-90679 - Article's Language: EN
J Oncol Sci. 2022;8(2):100-6
This is an open access article under the CC BY-NC-ND license
Objective: We investigated the prognostic and predictive effects of the ABO blood group system on patients receiving immune checkpoint inhibitors for advanced renal cell carcinoma (RCC). Material and Methods: In this retrospective observational study, the data on the patients with known ABO blood group, who were administered nivolumab for mRCC, were reviewed. The tumor response rates and survival were analyzed based on the ABO blood group. Results: A total of 89 patients were included in the study. The median age of the patients was 57 (range: 24-83 years) years, and 67% (n=60) of the patients were male. Moreover, 43%, 18%, 9%, and 30% of the patients had blood groups A, B, AB, and O, respectively. Our study had a median follow-up time of 11 months. Although the groups did not differ significantly in progression-free survival (PFS) and overall survival (OS) according to the blood groups, patients who had the B blood type survived longer. For patients with blood types A, B, AB, and O, the median PFS was 5.3 months, 8.4 months, 3.7 months, and 7.8 months, respectively (p=0.8), and the median OS was 14.5 months, 20.3 months, 12.0 months, and 16.5 months, respectively (p=0.8). Conclusion: Although the groups did not differ significantly according to the ABO blood group, the patients with the B blood group survived relatively longer. These results suggested that further studies with more patients should be conducted.
  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [Crossref]  [PubMed] 
  2. Tran J, Ornstein MC. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncol Pract. 2022;18(3):187-96. [Crossref]  [PubMed] 
  3. Navani V, Heng DYC. Treatment selection in first-line metastatic renal cell carcinoma-the contemporary treatment paradigm in the age of combination therapy: a review. JAMA Oncol. 2022;8(2):292-9. [Crossref]  [PubMed] 
  4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Kidney Cancer. April 10, 2022. [Crossref] 
  5. Raimondi A, Sepe P, Zattarin E, et al. Predictive biomarkers of response to immunotherapy in metastatic renal cell cancer. Front Oncol. 2020;10:1644. [Crossref]  [PubMed]  [PMC] 
  6. Van Alsten SC, Aversa JG, Santo L, et al. Association between ABO and Duffy blood types and circulating chemokines and cytokines. Genes Immun. 2021;22(3):161-71. [PubMed]  [PMC] 
  7. Franchini M, Liumbruno GM, Lippi G. The prognostic value of ABO blood group in cancer patients. Blood Transfus. 2016;14(5):434-40. [PubMed]  [PMC] 
  8. Ergun Y, Esen SA, Bardakci M, Ucar G, Kalkan Z, Urakci Z, et al. Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors. Cancer Biomark. 2022;34(2):329-36. [Crossref]  [PubMed] 
  9. Luiz C. de MattosHaroldo W. Moreira. Genetic of the ABO blood system and its link with the immune system. Rev. Bras. Hematol. Hemoter. 2004;26(1):60-3. [Crossref] 
  10. Barbalic M, Dupuis J, Dehghan A, et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet. 2010;19(9):1863-72. [PubMed]  [PMC] 
  11. Becker J, Pavlakovic H, Ludewig F, et al. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2. Clin Cancer Res. 2010;16(5):1431-41. [Crossref]  [PubMed]  [PMC] 
  12. Shibata MA, Ambati J, Shibata E, et al. The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model. BMC Med. 2010;8:69. [Crossref]  [PubMed]  [PMC] 
  13. Anthony HM. Blood groups and the response to immunotherapy. Cancer Immunol Immunother. 1981;11:287-9. [Crossref] 
  14. Muthana SM, Gulley JL, Hodge JW, et al. ABO blood type correlates with survival on prostate cancer vaccine therapy. Oncotarget. 2015;6(31):32244-56. [Crossref]  [PubMed]  [PMC]